Ecological Succession of Polymicrobial Communities in the Cystic Fibrosis Airways
- PMID: 33262240
- PMCID: PMC7716390
- DOI: 10.1128/mSystems.00809-20
Ecological Succession of Polymicrobial Communities in the Cystic Fibrosis Airways
Abstract
Antimicrobial therapies against cystic fibrosis (CF) lung infections are largely aimed at the traditional, well-studied CF pathogens such as Pseudomonas aeruginosa and Burkholderia cepacia complex, despite the fact that the CF lung harbors a complex and dynamic polymicrobial community. A clinical focus on the dominant pathogens ignores potentially important community-level interactions in disease pathology, perhaps explaining why these treatments are often less effective than predicted based on in vitro testing. A better understanding of the ecological dynamics of this ecosystem may enable clinicians to harness these interactions and thereby improve treatment outcomes. Like all ecosystems, the CF lung microbial community develops through a series of stages, each of which may present with distinct microbial communities that generate unique host-microbe and microbe-microbe interactions, metabolic profiles, and clinical phenotypes. While insightful models have been developed to explain some of these stages and interactions, there is no unifying model to describe how these infections develop and persist. Here, we review current perspectives on the ecology of the CF airway and present the CF Ecological Succession (CFES) model that aims to capture the spatial and temporal complexity of CF lung infection, address current challenges in disease management, and inform the development of ecologically driven therapeutic strategies.
Keywords: Pseudomonas aeruginosa; anaerobic bacteria; cystic fibrosis; ecological succession; microbial ecology; microbiome; polymicrobial infections; pulmonary exacerbations.
Copyright © 2020 Khanolkar et al.
Figures
Similar articles
-
Polymicrobial Interactions in the Cystic Fibrosis Airway Microbiome Impact the Antimicrobial Susceptibility of Pseudomonas aeruginosa.Antibiotics (Basel). 2021 Jul 7;10(7):827. doi: 10.3390/antibiotics10070827. Antibiotics (Basel). 2021. PMID: 34356747 Free PMC article. Review.
-
The airway microbiome in cystic fibrosis and implications for treatment.Curr Opin Pediatr. 2011 Jun;23(3):319-24. doi: 10.1097/MOP.0b013e32834604f2. Curr Opin Pediatr. 2011. PMID: 21494150 Review.
-
Metabolic Modeling of Cystic Fibrosis Airway Communities Predicts Mechanisms of Pathogen Dominance.mSystems. 2019 Apr 23;4(2):e00026-19. doi: 10.1128/mSystems.00026-19. eCollection 2019 Mar-Apr. mSystems. 2019. PMID: 31020043 Free PMC article.
-
The polymicrobial nature of airway infections in cystic fibrosis: Cangene Gold Medal Lecture.Can J Microbiol. 2011 Feb;57(2):69-77. doi: 10.1139/w10-105. Can J Microbiol. 2011. PMID: 21326348 Review.
-
Tobramycin-Treated Pseudomonas aeruginosa PA14 Enhances Streptococcus constellatus 7155 Biofilm Formation in a Cystic Fibrosis Model System.J Bacteriol. 2015 Oct 19;198(2):237-47. doi: 10.1128/JB.00705-15. Print 2016 Jan 15. J Bacteriol. 2015. PMID: 26483523 Free PMC article.
Cited by
-
Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis.Clin Microbiol Rev. 2024 Sep 12;37(3):e0021521. doi: 10.1128/cmr.00215-21. Epub 2024 Aug 19. Clin Microbiol Rev. 2024. PMID: 39158301 Review.
-
Ceragenin-mediated disruption of Pseudomonas aeruginosa biofilms.PLoS One. 2024 Feb 12;19(2):e0298112. doi: 10.1371/journal.pone.0298112. eCollection 2024. PLoS One. 2024. PMID: 38346040 Free PMC article.
-
Autolysis of Pseudomonas aeruginosa Quorum-Sensing Mutant Is Suppressed by Staphylococcus aureus through Iron-Dependent Metabolism.J Microbiol Biotechnol. 2024 Apr 28;34(4):795-803. doi: 10.4014/jmb.2312.12028. Epub 2024 Feb 2. J Microbiol Biotechnol. 2024. PMID: 38303126 Free PMC article.
-
Integrating airway microbiome and blood proteomics data to identify multi-omic networks associated with response to pulmonary infection.Microbe. 2023 Dec;1:100023. doi: 10.1016/j.microb.2023.100023. Epub 2023 Nov 28. Microbe. 2023. PMID: 38264413 Free PMC article.
-
Transcriptional profiling and genetic analysis of a cystic fibrosis airway-relevant model shows asymmetric responses to growth in a polymicrobial community.Microbiol Spectr. 2023 Sep 29;11(5):e0220123. doi: 10.1128/spectrum.02201-23. Online ahead of print. Microbiol Spectr. 2023. PMID: 37772884 Free PMC article.
References
-
- Cystic Fibrosis Foundation. 2018. Cystic Fibrosis Foundation annual report. Cystic Fibrosis Foundation, Bethesda, MD.
-
- Flume PA, Mogayzel PJ Jr, Robinson KA, Rosenblatt RL, Quittell L, Marshall BC. Clinical Practice Guidelines for Pulmonary Therapies Committee, Cystic Fibrosis Foundation Pulmonary Therapies Committee. 2010. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 182:298–306. doi:10.1164/rccm.201002-0157OC. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources